Graphite < Graves Disease < Graves Ophthalmopathy

Facettes :

List of bibliographic references

Number of relevant bibliographic references: 31.
[0-20] [0 - 20][0 - 31][20-30][20-40]

Ident.	Authors (with country if any)	Title
001D62 (2009)		[Thymic hyperplasia in a patient with Graves' disease].
003005 (2005)		Recombinant thyrotropin-induced orbital uptake of [111In-diethylenetriamine-pentacetic acid-D-Phe1]octreotide in a patient with inactive Graves' ophthalmopathy.
003048 (2004)		Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy.
003053 (2005)		Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study.
003316 (2003)		[Octreotide scintigraphy for the diagnosis of active Graves' ophthalmopathy].
003616 (2002)		SPECT using 99mTc-DTPA for the assessment of disease activity in Graves' ophthalmopathy: a comparison with the results from MRI.
003772 (2002)		Octreoscan in thyroid-associated ophthalmopathy.
003971 (2001)		Imaging in thyroid-associated orbitopathy.
003B18 (2000)		Somatostatin-receptor scintigraphy in Graves' disease: reproducibility and variance of orbital activity.
003B55 (2000)		Clinical implications of somatostatin-receptor scintigraphy in ophthalmic Graves' disease.
003C03 (2000)		Uptake of In-111 octreotide in the retrobulbar space in a patient with thyroid ophthalmopathy.
003D63 (1999)		111In-pentetreotide scintigraphy in thyroid-associated orbitopathy.
003E37 (1999)		Octreotide-scintigraphy is a disease-activity parameter in Graves' ophthalmopathy.
003E62 (1999)		Somatostatin receptor scintigraphy to predict the clinical evolution and therapeutic response of thyroid-associated ophthalmopathy.
003E97 (1999)		The role of octreoscan in thyroid eye disease.
003F50 (1999)		Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease.
004028 (1998)		Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.
004167 (1998)		Indium-111-pentetreotide in Graves' disease.
004201 (1997)		Octreoscan in Graves' ophthalmopathy.
004421 (1997)		Evaluation of immunological mechanisms mediating thyroid-associated ophthalmopathy by radionuclide imaging using the somatostatin analog 111In-octreotide.
004657 (1996)		Somatostatin-receptor scintigraphy in Graves' orbitopathy.

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=IndiumV2/Data/Main/Curation

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/MedMesh.i -k "Graves Disease" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/MedMesh.i  \
                -Sk "Graves Disease" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=   *** parameter Area/wikiCode missing *** 
   |area=    IndiumV2
   |flux=    Main
   |étape=   Curation
   |type=    indexItem
   |index=    MedMesh.i
   |clé=    Graves Disease
}}

---

This area was generated with Dilib version V0.5.76. Data generation: Tue May 20 07:24:43 2014. Site generation: Thu Mar 7 11:12:53 2024